Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Analyst Perspectives | Discover varied analyst views on Neuronetics' potential, with price targets ranging from $7.00 to $7.00, reflecting confidence in the company's growth trajectory |
Market Expansion Strategies | Delve into Neuronetics' innovative approaches, including SPRAVATO rollout and PCP referral focus, driving clinic utilization and patient acquisition |
Financial Resilience | Explore Neuronetics' impressive 54% revenue growth, healthy gross margins, and strategic moves to achieve cash flow break-even by Q4 2025 |
Mental Health Tech Pionee | Neuronetics leads non-invasive neuromodulation therapies, showcasing robust revenue growth and strategic initiatives in the mental health secto |
Metrics to compare | STIM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSTIMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.7x | −3.0x | −0.6x | |
PEG Ratio | −0.07 | 0.03 | 0.00 | |
Price / Book | 4.4x | 4.3x | 2.6x | |
Price / LTM Sales | 0.9x | 3.1x | 3.4x | |
Upside (Analyst Target) | 295.5% | 28.9% | 40.2% | |
Fair Value Upside | Unlock | 10.5% | 4.8% | Unlock |